 Eduardo Davila
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 9 | 2025 | 910 | 1.930 |
Why?
| | Melanoma | 7 | 2024 | 757 | 1.920 |
Why?
| | Antigens, Neoplasm | 5 | 2024 | 316 | 1.690 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 3 | 2020 | 30 | 1.480 |
Why?
| | Neoplasms | 9 | 2025 | 2687 | 1.480 |
Why?
| | T-Lymphocytes | 11 | 2024 | 1985 | 1.430 |
Why?
| | Myeloid Differentiation Factor 88 | 7 | 2021 | 105 | 1.200 |
Why?
| | Toll-Like Receptor 2 | 4 | 2016 | 117 | 1.130 |
Why?
| | Melanoma, Experimental | 5 | 2016 | 111 | 1.090 |
Why?
| | Immunotherapy | 5 | 2021 | 633 | 0.940 |
Why?
| | Signal Transduction | 6 | 2025 | 5092 | 0.930 |
Why?
| | Immunotherapy, Adoptive | 7 | 2025 | 349 | 0.930 |
Why?
| | Chromones | 3 | 2024 | 44 | 0.920 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 16 | 0.900 |
Why?
| | Morpholines | 3 | 2024 | 124 | 0.870 |
Why?
| | Toll-Like Receptors | 4 | 2013 | 189 | 0.830 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 907 | 0.820 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 718 | 0.760 |
Why?
| | Cancer Vaccines | 2 | 2019 | 166 | 0.730 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1742 | 0.710 |
Why?
| | Cell Engineering | 1 | 2021 | 14 | 0.710 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 159 | 0.700 |
Why?
| | Apoptosis | 6 | 2020 | 2551 | 0.690 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 26 | 0.670 |
Why?
| | Lymphocyte Activation | 9 | 2025 | 1148 | 0.650 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 668 | 0.620 |
Why?
| | Immunity, Innate | 1 | 2025 | 825 | 0.620 |
Why?
| | Caspase 3 | 1 | 2020 | 251 | 0.610 |
Why?
| | Antineoplastic Agents | 4 | 2015 | 2152 | 0.600 |
Why?
| | CD8 Antigens | 2 | 2017 | 75 | 0.600 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 215 | 0.590 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 633 | 0.590 |
Why?
| | Dendritic Cells | 2 | 2019 | 491 | 0.590 |
Why?
| | Animals | 31 | 2025 | 37243 | 0.580 |
Why?
| | Mice | 24 | 2025 | 17828 | 0.580 |
Why?
| | Mice, Inbred NOD | 7 | 2025 | 593 | 0.570 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 95 | 0.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1395 | 0.540 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 464 | 0.530 |
Why?
| | Mice, SCID | 6 | 2025 | 368 | 0.510 |
Why?
| | Toll-Like Receptor 1 | 1 | 2016 | 12 | 0.500 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 26 | 0.500 |
Why?
| | Genetic Variation | 1 | 2021 | 990 | 0.480 |
Why?
| | Gamma Rays | 2 | 2023 | 56 | 0.470 |
Why?
| | T-Lymphocyte Subsets | 4 | 2021 | 416 | 0.470 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 174 | 0.470 |
Why?
| | Flagellin | 1 | 2015 | 17 | 0.460 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 870 | 0.460 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2023 | 68 | 0.460 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 663 | 0.450 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3397 | 0.440 |
Why?
| | Pyridines | 1 | 2017 | 494 | 0.410 |
Why?
| | Benzimidazoles | 1 | 2015 | 177 | 0.410 |
Why?
| | Antibodies, Monoclonal | 4 | 2012 | 1437 | 0.400 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2017 | 225 | 0.400 |
Why?
| | Neoplasm Proteins | 3 | 2024 | 433 | 0.390 |
Why?
| | Cell Proliferation | 7 | 2020 | 2480 | 0.390 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 205 | 0.390 |
Why?
| | Oligodeoxyribonucleotides | 2 | 2003 | 143 | 0.380 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2019 | 1097 | 0.370 |
Why?
| | Mice, Knockout | 5 | 2024 | 3029 | 0.310 |
Why?
| | Humans | 32 | 2025 | 138972 | 0.300 |
Why?
| | B7-H1 Antigen | 3 | 2020 | 216 | 0.290 |
Why?
| | Adoptive Transfer | 2 | 2008 | 221 | 0.290 |
Why?
| | Thymoma | 2 | 2010 | 36 | 0.280 |
Why?
| | Cell Survival | 5 | 2017 | 1126 | 0.280 |
Why?
| | Toll-Like Receptor 9 | 1 | 2007 | 33 | 0.270 |
Why?
| | CTLA-4 Antigen | 2 | 2025 | 99 | 0.270 |
Why?
| | Mice, Inbred C57BL | 7 | 2019 | 5801 | 0.270 |
Why?
| | Response Elements | 1 | 2007 | 90 | 0.270 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2017 | 40 | 0.250 |
Why?
| | Immunomodulation | 2 | 2017 | 99 | 0.240 |
Why?
| | Papio | 1 | 2006 | 94 | 0.240 |
Why?
| | Protein Kinases | 1 | 2007 | 308 | 0.240 |
Why?
| | Receptors, Pattern Recognition | 1 | 2025 | 12 | 0.240 |
Why?
| | Transplantation, Heterologous | 1 | 2006 | 193 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 501 | 0.230 |
Why?
| | Antigens, CD | 3 | 2021 | 537 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 37 | 0.230 |
Why?
| | Diphtheria Toxin | 1 | 2025 | 65 | 0.220 |
Why?
| | Immunotoxins | 1 | 2025 | 55 | 0.220 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1746 | 0.220 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 19 | 0.210 |
Why?
| | Protein Binding | 3 | 2021 | 2233 | 0.210 |
Why?
| | Immunodominant Epitopes | 1 | 2003 | 27 | 0.200 |
Why?
| | Antigens, Differentiation | 1 | 2003 | 82 | 0.200 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2003 | 68 | 0.200 |
Why?
| | Swine | 1 | 2006 | 800 | 0.200 |
Why?
| | CpG Islands | 1 | 2003 | 159 | 0.200 |
Why?
| | Sarcoma | 1 | 2025 | 189 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 85 | 0.190 |
Why?
| | Dinucleoside Phosphates | 1 | 2002 | 27 | 0.190 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2171 | 0.190 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 386 | 0.190 |
Why?
| | Cell Communication | 2 | 2019 | 316 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 112 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2003 | 123 | 0.180 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 237 | 0.180 |
Why?
| | Antigen Presentation | 2 | 2017 | 219 | 0.180 |
Why?
| | CD3 Complex | 1 | 2021 | 104 | 0.170 |
Why?
| | Skin Neoplasms | 1 | 2008 | 837 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 135 | 0.170 |
Why?
| | Semaphorins | 1 | 2021 | 35 | 0.170 |
Why?
| | Genetic Engineering | 1 | 2021 | 93 | 0.170 |
Why?
| | Lymphoma, T-Cell | 1 | 2020 | 28 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 153 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4316 | 0.160 |
Why?
| | Immunologic Memory | 1 | 2002 | 357 | 0.160 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 570 | 0.160 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 168 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 32 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2006 | 707 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 349 | 0.150 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 15 | 0.150 |
Why?
| | Cytokines | 3 | 2012 | 2083 | 0.150 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 59 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 197 | 0.150 |
Why?
| | Leukemia | 1 | 2021 | 241 | 0.140 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 956 | 0.140 |
Why?
| | HLA-A2 Antigen | 2 | 2010 | 49 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 661 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | 1 | 2017 | 2 | 0.140 |
Why?
| | Transplantation Tolerance | 1 | 2018 | 37 | 0.140 |
Why?
| | Jurkat Cells | 2 | 2015 | 138 | 0.140 |
Why?
| | Cells, Cultured | 3 | 2019 | 4182 | 0.140 |
Why?
| | CD55 Antigens | 1 | 2017 | 29 | 0.140 |
Why?
| | Gene Duplication | 1 | 2017 | 65 | 0.140 |
Why?
| | Genes, MHC Class I | 1 | 2017 | 36 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2017 | 45 | 0.130 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2017 | 47 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1473 | 0.130 |
Why?
| | Receptors, Virus | 1 | 2017 | 94 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 621 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2021 | 737 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1165 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 549 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 333 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2015 | 14 | 0.120 |
Why?
| | TNF Receptor-Associated Factor 6 | 1 | 2015 | 5 | 0.120 |
Why?
| | Immune Tolerance | 1 | 2017 | 366 | 0.120 |
Why?
| | Nitrophenols | 1 | 2015 | 32 | 0.110 |
Why?
| | Antigens | 2 | 2007 | 356 | 0.110 |
Why?
| | Female | 11 | 2025 | 74016 | 0.110 |
Why?
| | MCF-7 Cells | 1 | 2015 | 123 | 0.110 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 249 | 0.110 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 61 | 0.110 |
Why?
| | Vincristine | 1 | 2015 | 129 | 0.110 |
Why?
| | Protein Stability | 1 | 2015 | 176 | 0.110 |
Why?
| | Vaccination | 1 | 2003 | 1438 | 0.110 |
Why?
| | Drug Synergism | 1 | 2015 | 367 | 0.110 |
Why?
| | Interferon-gamma | 2 | 2010 | 787 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 205 | 0.100 |
Why?
| | Antifreeze Proteins | 1 | 2013 | 1 | 0.100 |
Why?
| | Gadus morhua | 1 | 2013 | 1 | 0.100 |
Why?
| | Glioma | 1 | 2018 | 403 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2015 | 366 | 0.100 |
Why?
| | Fish Proteins | 1 | 2013 | 10 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2017 | 1192 | 0.100 |
Why?
| | Galectin 3 | 1 | 2013 | 19 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 20 | 0.100 |
Why?
| | Receptors, Antigen | 1 | 2012 | 16 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2012 | 53 | 0.100 |
Why?
| | Piperazines | 1 | 2015 | 345 | 0.090 |
Why?
| | Weight Reduction Programs | 1 | 2013 | 118 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2015 | 731 | 0.090 |
Why?
| | Male | 8 | 2025 | 68250 | 0.090 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1355 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1235 | 0.090 |
Why?
| | Transcriptome | 1 | 2018 | 966 | 0.090 |
Why?
| | High-Throughput Screening Assays | 1 | 2013 | 157 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2011 | 5 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1487 | 0.090 |
Why?
| | Sulfonamides | 1 | 2015 | 505 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1244 | 0.090 |
Why?
| | Lymphocytes | 1 | 2013 | 395 | 0.090 |
Why?
| | Mobile Applications | 1 | 2013 | 178 | 0.090 |
Why?
| | Behavior Therapy | 1 | 2013 | 273 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 819 | 0.080 |
Why?
| | Perforin | 1 | 2010 | 19 | 0.080 |
Why?
| | Social Media | 1 | 2013 | 159 | 0.080 |
Why?
| | Cell Movement | 1 | 2015 | 969 | 0.080 |
Why?
| | Granzymes | 1 | 2010 | 50 | 0.080 |
Why?
| | Down-Regulation | 2 | 2019 | 636 | 0.080 |
Why?
| | T-Box Domain Proteins | 1 | 2010 | 98 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 3984 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4095 | 0.080 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 461 | 0.080 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 213 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 252 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 252 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1267 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 368 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1034 | 0.070 |
Why?
| | Checkpoint Kinase 2 | 1 | 2007 | 29 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1701 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1767 | 0.070 |
Why?
| | Checkpoint Kinase 1 | 1 | 2007 | 28 | 0.070 |
Why?
| | Whole-Body Irradiation | 1 | 2007 | 78 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2007 | 44 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 416 | 0.070 |
Why?
| | Radiation Tolerance | 1 | 2007 | 96 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2013 | 882 | 0.060 |
Why?
| | DNA Repair | 1 | 2007 | 229 | 0.060 |
Why?
| | Ligands | 1 | 2007 | 666 | 0.060 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 96 | 0.060 |
Why?
| | B7-2 Antigen | 1 | 2005 | 28 | 0.060 |
Why?
| | CD56 Antigen | 1 | 2005 | 34 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2005 | 56 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1046 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 241 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 157 | 0.060 |
Why?
| | Clone Cells | 1 | 2005 | 265 | 0.060 |
Why?
| | Rituximab | 1 | 2006 | 202 | 0.060 |
Why?
| | Cell Cycle | 1 | 2007 | 593 | 0.060 |
Why?
| | Synovial Membrane | 1 | 2005 | 121 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2005 | 327 | 0.050 |
Why?
| | Doxorubicin | 1 | 2025 | 350 | 0.050 |
Why?
| | Thymus Neoplasms | 1 | 2003 | 25 | 0.050 |
Why?
| | Abatacept | 1 | 2003 | 56 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 254 | 0.050 |
Why?
| | Vaccines, Subunit | 1 | 2003 | 50 | 0.050 |
Why?
| | CD4 Antigens | 1 | 2003 | 141 | 0.050 |
Why?
| | Graft Rejection | 1 | 2006 | 534 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2002 | 166 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 123 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 32 | 0.040 |
Why?
| | Graft vs Tumor Effect | 1 | 2021 | 8 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2591 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 88 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 79 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 2994 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2006 | 790 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1002 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 814 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 406 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2879 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2159 | 0.040 |
Why?
| | L-Selectin | 1 | 2019 | 24 | 0.040 |
Why?
| | Receptors, CCR7 | 1 | 2019 | 32 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2176 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2925 | 0.040 |
Why?
| | Benzothiazoles | 1 | 2017 | 35 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 73 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 176 | 0.030 |
Why?
| | Species Specificity | 1 | 2018 | 581 | 0.030 |
Why?
| | Dogs | 1 | 2018 | 425 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 462 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 627 | 0.030 |
Why?
| | Computers, Handheld | 1 | 2013 | 25 | 0.030 |
Why?
| | Immunomagnetic Separation | 1 | 2013 | 4 | 0.030 |
Why?
| | Centrifugation, Density Gradient | 1 | 2013 | 40 | 0.030 |
Why?
| | Aged | 2 | 2025 | 24172 | 0.030 |
Why?
| | Electronic Mail | 1 | 2013 | 62 | 0.030 |
Why?
| | HT29 Cells | 1 | 2013 | 41 | 0.030 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2013 | 8 | 0.030 |
Why?
| | Waist Circumference | 1 | 2013 | 140 | 0.030 |
Why?
| | K562 Cells | 1 | 2013 | 91 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 650 | 0.020 |
Why?
| | Proteome | 1 | 2017 | 471 | 0.020 |
Why?
| | Cell Phone | 1 | 2013 | 76 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3143 | 0.020 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 107 | 0.020 |
Why?
| | Middle Aged | 2 | 2025 | 33782 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 296 | 0.020 |
Why?
| | Universities | 1 | 2013 | 434 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 667 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3313 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 628 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 996 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5591 | 0.020 |
Why?
| | Overweight | 1 | 2013 | 573 | 0.020 |
Why?
| | Students | 1 | 2013 | 627 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 780 | 0.020 |
Why?
| | Adult | 2 | 2025 | 38393 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 2390 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 13371 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 21581 | 0.010 |
Why?
|
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|